Suppr超能文献

白塞病合并布加综合征

Behcet's disease in Budd-Chiari syndrome.

作者信息

Desbois Anne Claire, Rautou Pierre Emmanuel, Biard Lucie, Belmatoug Nadia, Wechsler Bertrand, Resche-Rigon Mathieu, Zarrouk Virginie, Fantin Bruno, de Chambrun M Pineton, Cacoub Patrice, Valla Dominique, Saadoun David, Plessier Aurélie

机构信息

Department of Internal Medicine and clinical Immunology APHP, Paris France, Centre de référence des maladies autoimmunes et systémiques rares, Université Pierre et Marie Curie, Paris 6, Paris, France ; Laboratory I3 "Immunology, Immunopathology, Immunotherapy", UMR CNRS 7211, INSERM U959, Groupe Hospitalier Pitié-Salpetrière, DHU I2B Inflammation, Immunopathology, Biotherapy, Université Pierre et Marie Curie, Paris 6, Paris, France.

Department of Hepatology; Hôpital Beaujon, INSERM U773, Service d'hépatologie, 100 boulevard du Général Leclerc, 92118 Clichy cedex, France.

出版信息

Orphanet J Rare Dis. 2014 Sep 13;9:104. doi: 10.1186/s13023-014-0153-1. eCollection 2014.

Abstract

BACKGROUND

Behcet's disease (BD) is a well-known cause of Budd-Chiari syndrome (BCS). Data are lacking on the presentation and outcome of BCS related to BD.

METHODS

We investigated the relationship between BD and BCS in 14 patients with both diseases and compared the results to 92 BCS patients without BD.

RESULTS

Male gender (p = 0.003), North African origin (P = 0.007) and inferior vena cava obstruction (P < 0.0001) were more frequent in patients with BD and BCS than in those with BCS alone and the plasma C-reactive protein level was higher (p = 0.003). Two of the patients with the combined diseases underwent recanalization of the vena cava and the hepatic veins, none received transjugular intrahepatic portosystemic shunts (TIPS), one received a surgical shunt and one underwent liver transplantation. TIPS were less frequent in patients with BD and BCS than in those with BCS alone (P = 0.019). Eighty six per cent of patients with BCS and BD received corticosteroids and immunosuppressive therapy. The 5-year transplantation-free survival rate was 63% in patients with BCS alone and 91% in those without BD (P = 0.11). In our series and in the literature, a high number of patients [12 (61.5%) and 11 (64.7%) respectively] treated with anticoagulation and corticosteroids and/or immunosuppressants did not require invasive treatment.

CONCLUSION

This study shows a higher frequency of IVC obstruction in patients with BCS and BD. Medical treatment with anticoagulation and immunosuppressive agents may improve the symptoms of BCS. Therefore early management with immunosuppressive and anticoagulation therapy appears to be the treatment of choice in patients with BCS and BD.

摘要

背景

白塞病(BD)是布加综合征(BCS)的一个已知病因。关于与BD相关的BCS的表现和结局的数据尚缺乏。

方法

我们调查了14例同时患有这两种疾病的患者中BD与BCS之间的关系,并将结果与92例无BD的BCS患者进行比较。

结果

与单纯BCS患者相比,BD合并BCS患者中男性(p = 0.003)、北非裔(P = 0.007)和下腔静脉阻塞(P < 0.0001)更为常见,且血浆C反应蛋白水平更高(p = 0.003)。两名合并疾病的患者接受了腔静脉和肝静脉再通术,无人接受经颈静脉肝内门体分流术(TIPS),一名接受了外科分流术,一名接受了肝移植。BD合并BCS患者接受TIPS的频率低于单纯BCS患者(P = 0.019)。86%的BCS合并BD患者接受了皮质类固醇和免疫抑制治疗。单纯BCS患者的5年无移植生存率为63%,无BD患者为91%(P = 0.11)。在我们的系列研究和文献中,大量接受抗凝和皮质类固醇和/或免疫抑制剂治疗的患者[分别为12例(61.5%)和11例(64.7%)]不需要侵入性治疗。

结论

本研究显示BCS合并BD患者中IVC阻塞的频率更高。抗凝和免疫抑制剂的药物治疗可能改善BCS的症状。因此,免疫抑制和抗凝治疗的早期管理似乎是BCS合并BD患者的首选治疗方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1b5d/4392879/5f182dc3ae8c/13023_2014_153_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验